首页 > 市场调查报告书 > 医疗设备

整形外科

市场调查报告书

商品编码

1493553

软骨再生市场 - 全球产业规模、份额、趋势、机会和预测，按类型、治疗方式（基于细胞、非细胞）、应用、地区和竞争细分，2019-2029F

Cartilage Regeneration Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment Modality (Cell-Based, Non-Cell Based ), By Application, By Region, and By Competition, 2019-2029F

出版日期: 2024年05月15日 | 出版商:

TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年全球软骨再生市场价值为14.1亿美元，预计到2029年预测期内将以17.35%的复合年增长率稳定增长。组织，对于维持关节功能和减轻与软骨缺陷和退化性关节疾病相关的症状至关重要。软骨是一种特殊的结缔组织，排列在关节内的骨表面上，在身体活动期间提供必要的缓衝、减震和平滑运动。各种疾病，包括外伤、骨关节炎、类风湿性关节炎和其他退化性关节疾病，都会损害软骨健康，导致缺陷、裂缝、侵蚀和组织完整性丧失，进而导致疼痛、发炎、僵硬和活动能力受损。

市场概况
预测期	2025-2029
2023 年市场规模	14.1亿美元
2029 年市场规模	36.7亿美元
2024-2029 年复合年增长率	17.35%
成长最快的细分市场	纤维软骨
最大的市场	北美洲

针对软骨损伤，身体的自然癒合机制可能会启动修復过程，可以透过物理治疗、运动和生活方式改变等疗法来增强修復过程，从而促进关节健康并减少发炎。生物和再生疗法利用细胞、生长因子和生物支架的再生潜力来刺激软骨修復和再生。这些疗法通常涉及间质干细胞（MSC）、软骨细胞、富含血小板的血浆（PRP）、生长因子和其他生物製剂，以增强组织癒合并诱导软骨形成。

组织工程、3D 生物列印和干细胞治疗等医疗技术的不断进步正在彻底改变软骨再生方法，从而产生更有效和创新的解决方案。这些进步有助于改善治疗结果，并扩大可以从软骨再生疗法中受益的患者范围。患者和医疗保健专业人员对软骨再生可用选择的认识不断提高，推动了对这些疗法的需求。这种需求在老龄化人口中尤其明显，他们更容易患骨关节炎等退化性关节疾病。随着老年人口的增长，对软骨再生手术的需求相应增加，以解决与年龄相关的关节问题并提高老年人的生活品质。

关节镜检查和细胞疗法等微创外科手术的趋势是软骨再生领域的重要驱动力。患者和医疗保健提供者都更喜欢这些手术，因为与传统的手术干预相比，它们的併发症风险更低，恢復时间更短，术后疼痛更少。这一转变强调了先进技术的重要性，这些技术能够实现精确和微创的软骨修復和再生方法。

在持续研究、技术创新以及对解决软骨损伤和退化性关节疾病的有效解决方案日益增长的需求的推动下，软骨再生领域持续快速发展。透过利用细胞、生长因子和先进生物医学工程技术的再生潜力，软骨再生疗法有望改善关节健康、恢復活动能力并提高患有软骨相关疾病的患者的整体生活品质。

主要市场驱动因素

软骨再生的技术进步

提高意识和患者需求

对微创手术的偏好日益增长

主要市场挑战

软骨组织工程的复杂性

治疗费用高

主要市场趋势

骨关节炎和运动伤害的发生率上升

细分市场洞察

类型洞察

治疗方式见解

区域洞察

Global Cartilage Regeneration Market was valued at USD 1.41 billion in 2023 and is expected to experience a steady growth in the forecast period at a CAGR of 17.35% through 2029. Cartilage regeneration is a vital process aimed at restoring damaged or degenerated cartilage tissue within joints, crucial for maintaining joint function and alleviating symptoms associated with cartilage defects and degenerative joint diseases. Cartilage, a specialized connective tissue, lines bone surfaces within joints, providing essential cushioning, shock absorption, and smooth movement during physical activities. Various conditions, including traumatic injuries, osteoarthritis, rheumatoid arthritis, and other degenerative joint diseases, can compromise cartilage health, leading to defects, fissures, erosions, and loss of tissue integrity, resulting in pain, inflammation, stiffness, and impaired mobility.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 1.41 Billion
Market Size 2029	USD 3.67 Billion
CAGR 2024-2029	17.35 %
Fastest Growing Segment	Fibro Cartilage
Largest Market	North America

In response to cartilage injuries, the body's natural healing mechanisms may initiate repair processes, which can be augmented through therapies such as physical therapy, exercise, and lifestyle modifications, promoting joint health and reducing inflammation. Biological and regenerative therapies utilize the regenerative potential of cells, growth factors, and biological scaffolds to stimulate cartilage repair and regeneration. These therapies often involve mesenchymal stem cells (MSCs), chondrocytes, platelet-rich plasma (PRP), growth factors, and other biological agents to enhance tissue healing and induce cartilage formation.

Continual advancements in medical technologies, including tissue engineering, 3D bioprinting, and stem cell therapy, are revolutionizing cartilage regeneration approaches, resulting in more effective and innovative solutions. These advancements contribute to improved treatment outcomes and broaden the scope of patients who can benefit from cartilage regeneration therapies. Increased awareness among patients and healthcare professionals about available options for cartilage regeneration is driving demand for these therapies. This demand is particularly pronounced among the aging population, which is more susceptible to degenerative joint diseases like osteoarthritis. As the elderly population grows, there is a corresponding rise in demand for cartilage regeneration procedures to address age-related joint issues and enhance the quality of life for older individuals.

The trend towards minimally invasive surgical procedures, such as arthroscopy and cell-based therapies, is a significant driver in the field of cartilage regeneration. Patients and healthcare providers alike prefer these procedures due to their lower risk of complications, shorter recovery times, and reduced post-operative pain compared to traditional surgical interventions. This shift underscores the importance of advancing technologies that enable precise and minimally invasive approaches to cartilage repair and regeneration.

The field of cartilage regeneration continues to evolve rapidly, fueled by ongoing research, technological innovations, and increasing demand for effective solutions to address cartilage injuries and degenerative joint diseases. By harnessing the regenerative potential of cells, growth factors, and advanced biomedical engineering techniques, cartilage regeneration therapies hold promise for improving joint health, restoring mobility, and enhancing the overall quality of life for patients with cartilage-related conditions.

Key Market Drivers

Technological Advancements in Cartilage Regeneration

Tissue engineering plays a pivotal role in cartilage regeneration, involving the development of biomimetic scaffolds and matrices that mimic the native extracellular matrix of cartilage. These scaffolds provide structural support and facilitate cell attachment, proliferation, and differentiation. By seeding these constructs with chondrocytes or stem cells, either in vitro or in vivo, tissue-engineered scaffolds promote the regeneration of cartilage tissue. 3D bioprinting technology further enhances this process by enabling the precise deposition of cells, biomaterials, and growth factors to create complex, patient-specific cartilage constructs with controlled architecture and mechanical properties.

Stem cell therapy is another key approach in cartilage regeneration, utilizing multipotent or pluripotent stem cells like mesenchymal stem cells (MSCs) or induced pluripotent stem cells (iPSCs) to promote tissue repair. These cells can differentiate into chondrocytes and contribute to the formation of new cartilage tissue. Ongoing research explores advanced techniques such as gene editing and cell programming to enhance the regenerative potential of stem cells in cartilage repair. Biomaterials are integral to cartilage regeneration, providing a supportive environment for cell growth and tissue formation. Advances in biomaterial science have led to the development of biocompatible and bioresorbable materials, including hydrogels, polymers, and ceramics, engineered into porous scaffolds that mimic the native cartilage microenvironment. These materials facilitate cell infiltration and tissue integration, optimizing the regeneration process.

Biological factors and growth factors such as transforming growth factor-beta (TGF-B), bone morphogenetic proteins (BMPs), and insulin-like growth factor-1 (IGF-1) play crucial roles in regulating chondrogenesis and cartilage formation. Controlled delivery of these factors through biomaterial-based carriers or gene therapy approaches enhances the efficacy of cartilage regeneration therapies and promotes tissue healing. Minimally invasive surgical techniques like arthroscopy and percutaneous implantation are preferred for cartilage regeneration procedures as they minimize tissue trauma, reduce post-operative pain, and accelerate recovery times. These techniques enable targeted delivery of therapeutic agents and cell-based therapies to the site of cartilage injury, improving treatment precision and patient outcomes.

Regenerative medicine approaches such as platelet-rich plasma (PRP) therapy and autologous chondrocyte implantation (ACI) utilize the body's own cells and biological factors to promote cartilage repair. These personalized treatment options have shown promising results in clinical studies for repairing focal cartilage defects and early-stage osteoarthritis, contributing to the growth of the global cartilage regeneration market.

Increasing Awareness and Patient Demand

With the proliferation of information through the internet, social media, and healthcare providers, patients are becoming more informed about treatment options for cartilage defects and degenerative joint diseases. They are taking a proactive approach in exploring alternatives beyond traditional treatments like pain management or joint replacement surgery. Patients afflicted with cartilage defects often experience mobility limitations, pain, and a decreased quality of life. As awareness regarding the potential benefits of cartilage regeneration therapies grows, patients are seeking treatments that can alleviate symptoms, restore joint function, and enhance overall quality of life.

Cartilage regeneration therapies, such as stem cell therapy, platelet-rich plasma (PRP) injections, and autologous chondrocyte implantation (ACI), offer minimally invasive alternatives to conventional open surgeries. Patients prefer these less invasive procedures due to their shorter recovery times, reduced risk of complications, and preservation of joint integrity. Clinical studies and real-world evidence have demonstrated promising outcomes for cartilage regeneration therapies, including pain reduction, functional improvement, and cartilage repair. Positive treatment outcomes reported by patients and healthcare providers contribute to the increased demand for these therapies.

The aging population and the growing participation in sports and physical activities contribute to the rising prevalence of joint injuries and osteoarthritis. As more individuals experience cartilage defects and degenerative joint diseases, the demand for effective treatment options, including cartilage regeneration, continues to grow. Technological advancements in cartilage regeneration, such as tissue engineering, 3D bioprinting, and biomaterials, have expanded treatment options and improved outcomes for patients. Patients are increasingly aware of these advanced therapies and are seeking access to them to address their cartilage-related issues.

Patient advocacy organizations and support groups dedicated to musculoskeletal health and joint disorders play a crucial role in raising awareness about cartilage regeneration therapies. These groups provide information, support, and resources to patients, empowering them to advocate for their own care and explore treatment options. This growing awareness and advocacy contribute to the increasing demand for cartilage regeneration therapies, thereby driving the growth of the global Cartilage Regeneration Market.

Growing Preference for Minimally Invasive Procedures

Minimally invasive procedures represent a significant advancement in surgical techniques, offering several advantages over traditional open surgeries, particularly in the context of cartilage regeneration. These procedures involve smaller incisions or entry points, resulting in less post-operative pain and discomfort for patients. Patients experience improved satisfaction and faster recovery times compared to those undergoing open surgeries. The shorter recovery periods associated with minimally invasive techniques allow patients to return to their daily activities sooner, minimizing disruption to their lives and enhancing their overall quality of life.

Minimally invasive procedures are often associated with lower rates of surgical complications, such as infections, blood loss, and tissue damage. This reduced risk of complications provides patients with greater peace of mind and confidence in the safety of the procedure, contributing to their overall satisfaction with the treatment. Minimally invasive procedures aim to preserve the natural structure and integrity of the affected joint while addressing cartilage defects. Unlike traditional surgeries that may involve extensive tissue dissection and manipulation, minimally invasive techniques minimize trauma to surrounding tissues and reduce the risk of long-term joint damage. This preservation of tissue integrity is crucial for optimizing long-term joint function and preventing further deterioration of the joint.

Minimally invasive procedures often result in smaller scars and less visible surgical incisions compared to open surgeries. This can lead to improved cosmetic outcomes and enhanced patient satisfaction with the appearance of the surgical site, which is particularly important for patients undergoing procedures in visible areas. Many minimally invasive procedures for cartilage regeneration can be performed on an outpatient or same-day surgery basis, further enhancing patient convenience. Patients benefit from shorter hospital stays and reduced healthcare costs associated with inpatient care, leading to overall cost savings for both patients and healthcare systems.

Advances in surgical instrumentation, imaging technology, and surgical techniques have significantly expanded the range of minimally invasive options available for cartilage regeneration. These technological advancements enable surgeons to perform complex procedures with greater precision and control, leading to better treatment outcomes for patients. Ongoing research, and development efforts continue to refine and innovate minimally invasive techniques, further improving their efficacy and safety for cartilage regeneration procedures. The numerous benefits of minimally invasive procedures, including reduced post-operative pain, faster recovery times, lower complication rates, preservation of tissue integrity, improved cosmetic outcomes, and enhanced patient convenience, contribute to the growing demand for these techniques in the field of cartilage regeneration. The Global Cartilage Regeneration Market is expected to witness accelerated growth driven by the increasing adoption of minimally invasive procedures.

Key Market Challenges

Complexity of Cartilage Tissue Engineering

Cartilage is a highly specialized tissue with a complex hierarchical structure, including distinct layers of chondrocytes embedded in an extracellular matrix composed of collagen, proteoglycans, and water. Replicating this intricate structure in tissue-engineered constructs presents technical challenges in terms of biomaterial selection, scaffold design, and cell seeding techniques. Successful cartilage regeneration requires the engineered tissue to integrate seamlessly with surrounding native cartilage and underlying bone. Achieving functional integration between tissue-engineered constructs and host tissues is challenging due to differences in mechanical properties, biochemical composition, and cellular organization.

Maintaining the viability and functionality of cells within tissue-engineered constructs throughout the implantation process and post-implantation period is critical for successful cartilage regeneration. Factors such as nutrient diffusion, oxygen supply, and waste removal must be carefully controlled to support cell survival, proliferation, and differentiation within the engineered tissue. Controlling the differentiation of stem cells or progenitor cells into chondrocytes, the specialized cells responsible for producing cartilage matrix, is a key aspect of cartilage tissue engineering. Achieving and maintaining chondrogenic differentiation in vitro and in vivo environments while minimizing hypertrophic differentiation and fibrocartilage formation presents significant challenges.

Engineered cartilage constructs must possess appropriate mechanical properties, including stiffness, elasticity, and compressive strength, to withstand physiological loading and provide functional support to the joint. Balancing the mechanical properties of tissue-engineered constructs with their biological compatibility and degradation kinetics is a complex optimization process.

High Cost of Treatment

Many of the technologies and therapies used in cartilage regeneration, such as tissue engineering, stem cell therapy, and growth factor treatments, involve sophisticated processes and specialized equipment, leading to high production and treatment costs. Surgical procedures for cartilage regeneration, including autologous chondrocyte implantation (ACI) and matrix-induced autologous chondrocyte implantation (MACI), are often complex and time-consuming. The costs associated with operating room time, surgical equipment, and healthcare personnel contribute to the overall cost of treatment. Biological and regenerative therapies for cartilage regeneration, such as platelet-rich plasma (PRP) injections and mesenchymal stem cell (MSC) therapy, typically require specialized cell processing facilities, quality control measures, and regulatory compliance, adding to the cost of treatment. In many healthcare systems, insurance coverage for cartilage regeneration therapies may be limited or unavailable, leaving patients responsible for covering the full cost of treatment out-of-pocket.

This financial burden can be prohibitive for some patients and may deter them from pursuing potentially beneficial therapies. Cartilage regeneration therapies often require multiple treatment sessions or follow-up procedures to achieve optimal outcomes. The cumulative costs of repeated treatments, imaging studies, and rehabilitation services can further increase the overall cost of care for patients. Healthcare providers and payers may have concerns about the cost-effectiveness of cartilage regeneration therapies compared to traditional treatment modalities, such as physical therapy, anti-inflammatory medications, and joint replacement surgery. Demonstrating the long-term clinical and economic benefits of cartilage regeneration therapies is essential for widespread adoption and reimbursement.

Key Market Trends

Rising Incidence of Osteoarthritis and Sports Injuries

As the global population ages, the prevalence of osteoarthritis, a degenerative joint disease characterized by cartilage breakdown, is increasing. Aging is a primary risk factor for osteoarthritis, and as life expectancy rises, the number of individuals affected by this condition is also growing. Obesity is a significant risk factor for osteoarthritis, particularly in weight-bearing joints such as the knees and hips. The increasing prevalence of obesity worldwide contributes to a higher incidence of osteoarthritis and related joint complications, driving the demand for cartilage regeneration therapies. The popularity of sports and physical activities has increased globally, leading to a higher incidence of sports-related injuries, including ligament tears, meniscal tears, and cartilage damage. Athletes and active individuals are prone to joint injuries, which can accelerate the development of osteoarthritis and necessitate cartilage regeneration interventions. High-impact sports and activities, such as football, basketball, soccer, and running, place repetitive stress on joints and increase the risk of cartilage injuries and degeneration.

Professional athletes, recreational sports enthusiasts, and active individuals engaged in high-impact activities are at heightened risk for cartilage defects and osteoarthritis. Advances in diagnostic imaging modalities, such as magnetic resonance imaging (MRI) and arthroscopy, have improved the detection and diagnosis of cartilage lesions and osteoarthritic changes. More accurate and early diagnosis enables timely intervention and treatment of cartilage defects, driving demand for cartilage regeneration therapies. There is a growing trend towards conservative treatment approaches for cartilage injuries and early-stage osteoarthritis, emphasizing preservation of native joint tissue and function. Cartilage regeneration therapies offer minimally invasive alternatives to traditional surgical interventions, aligning with the preferences of patients and healthcare providers.

Segmental Insights

Type Insights

Based on the type, hyaline cartilage segment is projected to experience significant dominance in the Global Cartilage Regeneration Market during the forecast period. Hyaline cartilage is a specialized type of cartilage found in joints and is characterized by its smooth, durable, and low-friction surface. It plays a crucial role in facilitating joint movement and providing cushioning and support to the underlying bone. Hyaline cartilage defects are common in individuals with joint injuries, sports-related injuries, osteoarthritis, and other degenerative joint diseases. These defects can lead to pain, inflammation, stiffness, and impaired joint function, driving the need for effective cartilage regeneration therapies.

Hyaline cartilage has limited inherent regenerative capacity due to its avascular nature and low cellularity. Traditional treatment approaches, such as microfracture and mosaicplasty, have limitations in achieving durable and long-lasting repair of hyaline cartilage defects, leading to a growing demand for more advanced and effective regeneration strategies. Researchers and industry players are increasingly focusing on Hyaline cartilage tissue engineering as a promising approach for regenerating functional and durable cartilage tissue. Tissue engineering techniques aim to replicate the complex structure and biomechanical properties of hyaline cartilage using biomaterials, scaffolds, and cell-based therapies. Recent advancements in biomaterials, scaffold design, and bio fabrication technologies have enabled the development of innovative approaches for hyaline cartilage regeneration. These technologies allow for the creation of biomimetic scaffolds with tailored mechanical properties, biocompatibility, and bioactivity to support cell adhesion, proliferation, and differentiation.

Treatment Modality Insights

Based on the treatment, the cell-based segment is projected to experience rapid growth in the Global Cartilage Regeneration Market during the forecast period. Cell-based therapies harness the regenerative potential of cells, such as mesenchymal stem cells (MSCs) or chondrocytes, to promote cartilage repair and regeneration. These therapies offer a promising approach for addressing cartilage defects and degenerative joint diseases by stimulating the body's natural healing mechanisms. Cell-based therapies promote enhanced tissue integration and formation of hyaline-like cartilage, which closely resembles native cartilage tissue in terms of structure and function. This enables more durable and long-lasting repair of cartilage defects compared to traditional treatments. Many cell-based therapies for cartilage regeneration involve minimally invasive procedures, such as arthroscopy, where cells are implanted directly into the affected joint. These procedures offer benefits such as reduced post-operative pain, shorter recovery times, and lower risk of complications compared to open surgeries.

Recent advancements in tissue engineering techniques, biomaterials, and cell culture technologies have enhanced the efficacy and feasibility of cell-based cartilage regeneration therapies. Researchers and industry players are continuously innovating to optimize cell sources, scaffold materials, and delivery methods for improved treatment outcomes. There is a growing body of clinical evidence supporting the safety, efficacy, and long-term durability of cell-based cartilage regeneration therapies. Clinical studies have demonstrated promising results in terms of pain relief, functional improvement, and cartilage repair in patients with various joint injuries and degenerative conditions. Cell-based therapies for cartilage regeneration are being explored for a wide range of indications, including osteoarthritis, sports injuries, traumatic injuries, and degenerative joint diseases. This expanding scope of applications increases the potential market size and opportunities for growth in the cell-based segment.

Regional Insights

North America emerged as the dominant region in the Global Cartilage Regeneration Market in 2023. North America boasts advanced healthcare infrastructure, including state-of-the-art medical facilities, research institutions, and specialized healthcare providers. This infrastructure supports the development, adoption, and delivery of innovative cartilage regeneration therapies and procedures. The region is a hub for technological innovation in healthcare, with a strong emphasis on research and development. North American companies and academic institutions are at the forefront of developing novel cartilage regeneration technologies, such as tissue engineering, stem cell therapy, and 3D bioprinting.

North America has a high prevalence of joint injuries, sports-related injuries, and osteoarthritis, which drive demand for cartilage regeneration procedures. Factors such as an aging population, sedentary lifestyles, and participation in sports activities contribute to the increasing incidence of cartilage defects and degenerative joint diseases in the region. The regulatory framework governing healthcare and medical device approvals in North America is well-established and transparent. Regulatory agencies such as the Food and Drug Administration (FDA) in the United States provide clear guidelines for the approval and commercialization of cartilage regeneration products and therapies, fostering innovation and market growth.

Key Market Players

Osiris Therapeutics, Inc

Smith & Nephew Plc.

Vericel Corporation

Zimmer Biomet Holdings, Inc.

Medtronic Plc.

Stryker Corporation

Anika Therapeutics, Inc.

B. Braun SE

Orthocell Ltd.

Geistlich Pharma AG

Takeda Pharmaceutical Company Limited

CONMED Corporation

Report Scope:

In this report, the Global Cartilage Regeneration Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cartilage Regeneration Market, By Type:

Fibro Cartilage Hyaline Cartilage Elastic Cartilage Other

Cartilage Regeneration Market, By Treatment Modality:

Cell-Based

Chondrocyte

Transplantation

Growth Factor Technology

Non-Cell Based

Tissue Scaffolds

Cell-Free Composites

Cartilage Regeneration Market, By Application:

Knee Spine Ankle Hip Others

Cartilage Regeneration Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia-Pacific

China

Japan

India

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cartilage Regeneration Market.

Available Customizations:

Global Cartilage Regeneration market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cartilage Regeneration Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Fibro Cartilage, Hyaline Cartilage, Elastic Cartilage, Other)
- 5.2.2. By Treatment Modality (Cell-Based, Non-Cell Based)
  - 5.2.2.1. By Cell-Based (Chondrocyte, Transplantation, Growth Factor Technology)
  - 5.2.2.2. By Non-Cell Based (Tissue Scaffolds, Cell-Free Composites)
- 5.2.3. By Application (Knee, Spine, Ankle, Hip, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2023)
5.3. Market Map

6. North America Cartilage Regeneration Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Treatment Modality
- 6.2.3. By Application
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Cartilage Regeneration Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Treatment Modality
    - 6.3.1.2.3. By Application
- 6.3.2. Canada Cartilage Regeneration Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Treatment Modality
    - 6.3.2.2.3. By Application
- 6.3.3. Mexico Cartilage Regeneration Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Treatment Modality
    - 6.3.3.2.3. By Application

7. Europe Cartilage Regeneration Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Treatment Modality
- 7.2.3. By Application
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Cartilage Regeneration Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Treatment Modality
    - 7.3.1.2.3. By Application
- 7.3.2. United Kingdom Cartilage Regeneration Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Treatment Modality
    - 7.3.2.2.3. By Application
- 7.3.3. Italy Cartilage Regeneration Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Treatment Modality
    - 7.3.3.2.3. By Application
- 7.3.4. France Cartilage Regeneration Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Treatment Modality
    - 7.3.4.2.3. By Application
- 7.3.5. Spain Cartilage Regeneration Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Treatment Modality
    - 7.3.5.2.3. By Application

8. Asia-Pacific Cartilage Regeneration Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Treatment Modality
- 8.2.3. By Application
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Cartilage Regeneration Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Treatment Modality
    - 8.3.1.2.3. By Application
- 8.3.2. India Cartilage Regeneration Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Treatment Modality
    - 8.3.2.2.3. By Application
- 8.3.3. Japan Cartilage Regeneration Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Treatment Modality
    - 8.3.3.2.3. By Application
- 8.3.4. South Korea Cartilage Regeneration Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Treatment Modality
    - 8.3.4.2.3. By Application
- 8.3.5. Australia Cartilage Regeneration Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Treatment Modality
    - 8.3.5.2.3. By Application

9. South America Cartilage Regeneration Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Treatment Modality
- 9.2.3. By Application
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Cartilage Regeneration Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Treatment Modality
    - 9.3.1.2.3. By Application
- 9.3.2. Argentina Cartilage Regeneration Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Treatment Modality
    - 9.3.2.2.3. By Application
- 9.3.3. Colombia Cartilage Regeneration Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Treatment Modality
    - 9.3.3.2.3. By Application

10. Middle East and Africa Cartilage Regeneration Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Treatment Modality
- 10.2.3. By Application
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Cartilage Regeneration Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Treatment Modality
    - 10.3.1.2.3. By Application
- 10.3.2. Saudi Arabia Cartilage Regeneration Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Treatment Modality
    - 10.3.2.2.3. By Application
- 10.3.3. UAE Cartilage Regeneration Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Treatment Modality
    - 10.3.3.2.3. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. Competitive Landscape

14.1. Osiris Therapeutics, Inc
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Smith & Nephew Plc.
14.3. Vericel Corporation
14.4. Zimmer Biomet Holdings, Inc.
14.5. Medtronic Plc.
14.6. Stryker Corporation
14.7. Anika Therapeutics, Inc.
14.8. B. Braun SE
14.9. Orthocell Ltd.
14.10.Geistlich Pharma AG
14.11.Takeda Pharmaceutical Company Limited
14.12.CONMED Corporation

15. Strategic Recommendations

16. About Us & Disclaimer

02-2729-4219

+886-2-2729-4219

License/价格

软骨再生市场 - 全球产业规模、份额、趋势、机会和预测，按类型、治疗方式（基于细胞、非细胞）、应用、地区和竞争细分，2019-2029F

Cartilage Regeneration Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment Modality (Cell-Based, Non-Cell Based ), By Application, By Region, and By Competition, 2019-2029F

主要市场驱动因素

主要市场挑战

主要市场趋势

细分市场洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球软骨再生市场展望

第 6 章：北美软骨再生市场展望

第 7 章：欧洲软骨再生市场展望

第 8 章：亚太地区软骨再生市场展望

第 9 章：南美洲软骨再生市场展望

第 10 章：中东和非洲软骨再生市场展望

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：波特的五力分析

第14章：竞争格局

第 15 章：策略建议

第16章调查会社について・免责事项

Key Market Players

Report Scope:

Cartilage Regeneration Market, By Type:

Cartilage Regeneration Market, By Treatment Modality:

Cartilage Regeneration Market, By Application:

Cartilage Regeneration Market, By Region:

Competitive Landscape

Available Customizations:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Cartilage Regeneration Market Outlook

6. North America Cartilage Regeneration Market Outlook

7. Europe Cartilage Regeneration Market Outlook

8. Asia-Pacific Cartilage Regeneration Market Outlook

9. South America Cartilage Regeneration Market Outlook

10. Middle East and Africa Cartilage Regeneration Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Porter's Five Forces Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer